Neogenomics stock rating downgraded to Neutral by BTIG on execution concerns

Investing.com - BTIG downgraded Neogenomics (NASDAQ:NEO) from Buy to Neutral on Wednesday, citing concerns about management credibility and product portfolio alignment. The stock, currently trading at $5.25, has declined over 20% in the past week alone. According to InvestingPro analysis, the company appears undervalued relative to its Fair Value.

The research firm expressed skepticism about Neogenomics’ long-range plan, which maintains a 12-13% year-over-year revenue growth target but will be "de-emphasized" according to the new CEO’s explanation during the Q2 earnings call. While the company achieved 10.1% revenue growth in the last twelve months, InvestingPro data shows challenging metrics, including an extremely high EV/EBITDA multiple of 1,406x.

BTIG questioned whether Neogenomics’ product offerings align with pharmaceutical companies’ needs, noting that while some competitors continue to grow, Neogenomics has experienced declining performance for an extended period.

Additional concerns highlighted in the downgrade include Neogenomics’ "freedom to operate" in minimal residual disease (MRD) testing and challenges in establishing a stronger position in comprehensive genomic profiling, liquid biopsy, and next-generation sequencing markets where well-funded competitors already have established presences.

Despite previously defending Neogenomics based on its relatively low valuation compared to peers, BTIG now warns the stock "may be taking the form of a value trap" and would reconsider a more positive stance upon evidence of improved execution in intellectual property, MRD testing, and new product launches.

In other recent news, NeoGenomics reported its second-quarter 2025 earnings, showing an earnings per share (EPS) of $0.03, which exceeded analyst expectations of $0.02. However, the company fell short of revenue forecasts, posting $181 million against the anticipated $183 million. Following these results, NeoGenomics revised its full-year 2025 revenue and EBITDA guidance downward. In response to the earnings report, Needham adjusted its price target for NeoGenomics from $8.50 to $8.00, though it maintained a Buy rating. Meanwhile, William Blair downgraded the stock from Outperform to Market Perform, highlighting concerns about the time needed to restore investor confidence. These developments have sparked significant interest among investors, given the mixed earnings performance and subsequent analyst actions. The market’s reaction to these announcements has been closely watched, with analysts providing varying opinions on the company’s future trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.